PTAB rejects Vimovo IPR trial
Celgene fends off Kyle Bass challenge
Svetlana Lukienko / Shutterstock.com
Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review (IPR) challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Kyle Bass; PTAB; Vimovo; IPR; Coalition for Affordable Drugs; Pozen